Hansoh Pharma says Phase III LIGHTEN trial shows 19.3% weight loss at week 48 with olatorepatide 15 mg

By Public Technologies
  • Hansoh Pharma reported Phase III LIGHTEN results for olatorepatide at EASD 2026 in Milan as a late-breaking oral presentation.
  • The China study showed clinically meaningful weight loss over 48 weeks, with continued reduction suggesting no plateau by study end.
  • Safety looked consistent with the incretin class, with generally favorable gastrointestinal tolerability and no treatment-related discontinuations reported.
  • The readout supports olatorepatide’s positioning as a potential new weight-management drug, strengthening Hansoh’s late-stage metabolic pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.